627 related articles for article (PubMed ID: 36183651)
21. Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer.
Shitara K; Ajani JA; Moehler M; Garrido M; Gallardo C; Shen L; Yamaguchi K; Wyrwicz L; Skoczylas T; Bragagnoli AC; Liu T; Tehfe M; Elimova E; Bruges R; Zander T; de Azevedo S; Kowalyszyn R; Pazo-Cid R; Schenker M; Cleary JM; Yanez P; Feeney K; Karamouzis MV; Poulart V; Lei M; Xiao H; Kondo K; Li M; Janjigian YY
Nature; 2022 Mar; 603(7903):942-948. PubMed ID: 35322232
[TBL] [Abstract][Full Text] [Related]
22. Comprehensive biomarker analysis of long-term response to trastuzumab in patients with HER2-positive advanced gastric or gastroesophageal adenocarcinoma.
Porth I; Hirsch D; Ceribas Y; Weidner P; Weichert W; Götze TO; Perner S; Luley K; Heyer CM; de la Torre C; Hofheinz RD; Lorenzen S; Gaiser T
Eur J Cancer; 2023 Apr; 183():119-130. PubMed ID: 36848831
[TBL] [Abstract][Full Text] [Related]
23. Evolution of checkpoint inhibitors for the treatment of metastatic gastric cancers: Current status and future perspectives.
Taieb J; Moehler M; Boku N; Ajani JA; Yañez Ruiz E; Ryu MH; Guenther S; Chand V; Bang YJ
Cancer Treat Rev; 2018 May; 66():104-113. PubMed ID: 29730461
[TBL] [Abstract][Full Text] [Related]
24. Advances in immuno-oncology biomarkers for gastroesophageal cancer: Programmed death ligand 1, microsatellite instability, and beyond.
Lin EM; Gong J; Klempner SJ; Chao J
World J Gastroenterol; 2018 Jul; 24(25):2686-2697. PubMed ID: 29991874
[TBL] [Abstract][Full Text] [Related]
25. Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial.
Kang YK; Chen LT; Ryu MH; Oh DY; Oh SC; Chung HC; Lee KW; Omori T; Shitara K; Sakuramoto S; Chung IJ; Yamaguchi K; Kato K; Sym SJ; Kadowaki S; Tsuji K; Chen JS; Bai LY; Oh SY; Choda Y; Yasui H; Takeuchi K; Hirashima Y; Hagihara S; Boku N
Lancet Oncol; 2022 Feb; 23(2):234-247. PubMed ID: 35030335
[TBL] [Abstract][Full Text] [Related]
26. The effectivity of targeted therapy and immunotherapy in patients with advanced metastatic and non-metastatic cancer of the esophagus and esophago-gastric junction.
Valkema MJ; Mostert B; Lagarde SM; Wijnhoven BPL; van Lanschot JJB
Updates Surg; 2023 Feb; 75(2):313-323. PubMed ID: 35836094
[TBL] [Abstract][Full Text] [Related]
27. Immuno-Oncology Biomarkers for Gastric and Gastroesophageal Junction Adenocarcinoma: Why PD-L1 Testing May Not Be Enough.
Weinberg BA; Xiu J; Hwang JJ; Shields AF; Salem ME; Marshall JL
Oncologist; 2018 Oct; 23(10):1171-1177. PubMed ID: 29703766
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial.
Shitara K; Van Cutsem E; Bang YJ; Fuchs C; Wyrwicz L; Lee KW; Kudaba I; Garrido M; Chung HC; Lee J; Castro HR; Mansoor W; Braghiroli MI; Karaseva N; Caglevic C; Villanueva L; Goekkurt E; Satake H; Enzinger P; Alsina M; Benson A; Chao J; Ko AH; Wainberg ZA; Kher U; Shah S; Kang SP; Tabernero J
JAMA Oncol; 2020 Oct; 6(10):1571-1580. PubMed ID: 32880601
[TBL] [Abstract][Full Text] [Related]
29. Pembrolizumab for treatment of advanced gastric and gastroesophageal junction adenocarcinoma.
Joshi SS; Maron SB; Catenacci DV
Future Oncol; 2018 Feb; 14(5):417-430. PubMed ID: 29094609
[TBL] [Abstract][Full Text] [Related]
30. Efficacy of ramucirumab combination chemotherapy as second-line treatment in patients with advanced adenocarcinoma of the stomach or gastroesophageal junction after exposure to checkpoint inhibitors and chemotherapy as first-line therapy.
Masetti M; Al-Batran SE; Goetze TO; Thuss-Patience P; Knorrenschild JR; Goekkurt E; Folprecht G; Ettrich TJ; Lindig U; Luley KB; Pink D; Dechow T; Sookthai D; Junge S; Loose M; Pauligk C; Lorenzen S
Int J Cancer; 2024 Jun; 154(12):2142-2150. PubMed ID: 38447003
[TBL] [Abstract][Full Text] [Related]
31. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
32. Cost-effectiveness analysis of nivolumab plus chemotherapy vs chemotherapy for patients with unresectable advanced or metastatic HER2-negative gastric or gastroesophageal junction or esophageal adenocarcinoma in Japan.
Morimoto K; Moriwaki K; Shimozuma K; Nakayama T
J Gastroenterol; 2023 Dec; 58(12):1188-1197. PubMed ID: 37725256
[TBL] [Abstract][Full Text] [Related]
33. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
[TBL] [Abstract][Full Text] [Related]
34. The optimal threshold of PD-L1 combined positive score to predict the benefit of PD-1 antibody plus chemotherapy for patients with HER2-negative gastric adenocarcinoma: a meta-analysis.
Li JB; Lai MY; Lin ZC; Guan WL; Sun YT; Yang J; Wang WX; Yang ZR; Qiu MZ
Cancer Immunol Immunother; 2024 May; 73(7):132. PubMed ID: 38753055
[TBL] [Abstract][Full Text] [Related]
35. [New EMA drug approval: Nivolumab in association with chemotherapy as first line treatment for HER2-negative esophageal adenocarcinoma with PD-L1 expression (CPS≥5)].
Quesada S; Vaflard P
Bull Cancer; 2022 Feb; 109(2):109-110. PubMed ID: 34996599
[No Abstract] [Full Text] [Related]
36. Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study.
Bang YJ; Kang YK; Catenacci DV; Muro K; Fuchs CS; Geva R; Hara H; Golan T; Garrido M; Jalal SI; Borg C; Doi T; Yoon HH; Savage MJ; Wang J; Dalal RP; Shah S; Wainberg ZA; Chung HC
Gastric Cancer; 2019 Jul; 22(4):828-837. PubMed ID: 30911859
[TBL] [Abstract][Full Text] [Related]
37. Oncological outcomes of addition of anti-PD1/PD-L1 to chemotherapy in the therapy of patients with advanced gastric or gastro-oesophageal junction cancer: A meta-analysis.
Zheng Z; Guo Y; Zou CP
Medicine (Baltimore); 2020 Feb; 99(7):e18332. PubMed ID: 32049776
[TBL] [Abstract][Full Text] [Related]
38. First-Line Nivolumab and Relatlimab Plus Chemotherapy for Gastric or Gastroesophageal Junction Adenocarcinoma: The Phase II RELATIVITY-060 Study.
Hegewisch-Becker S; Mendez G; Chao J; Nemecek R; Feeney K; Van Cutsem E; Al-Batran SE; Mansoor W; Maisey N; Pazo Cid R; Burge M; Perez-Callejo D; Hipkin RW; Mukherjee S; Lei M; Tang H; Suryawanshi S; Kelly RJ; Tebbutt NC
J Clin Oncol; 2024 Jun; 42(17):2080-2093. PubMed ID: 38723227
[TBL] [Abstract][Full Text] [Related]
39. EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group.
Wagner AD; Grabsch HI; Mauer M; Marreaud S; Caballero C; Thuss-Patience P; Mueller L; Elme A; Moehler MH; Martens U; Kang YK; Rha SY; Cats A; Tokunaga M; Lordick F
BMC Cancer; 2019 May; 19(1):494. PubMed ID: 31126258
[TBL] [Abstract][Full Text] [Related]
40. First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial.
Janjigian YY; Maron SB; Chatila WK; Millang B; Chavan SS; Alterman C; Chou JF; Segal MF; Simmons MZ; Momtaz P; Shcherba M; Ku GY; Zervoudakis A; Won ES; Kelsen DP; Ilson DH; Nagy RJ; Lanman RB; Ptashkin RN; Donoghue MTA; Capanu M; Taylor BS; Solit DB; Schultz N; Hechtman JF
Lancet Oncol; 2020 Jun; 21(6):821-831. PubMed ID: 32437664
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]